Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.

The effect of mental illness, substance use, and treatment for depression on the initiation of highly active antiretroviral therapy among HIV-infected individuals.

Tegger MK, Crane HM, Tapia KA, Uldall KK, Holte SE, Kitahata MM.

AIDS Patient Care STDS. 2008 Mar;22(3):233-43. doi: 10.1089/apc.2007.0092.

PMID:
18290749
2.

Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy.

Pence BW, Miller WC, Gaynes BN, Eron JJ Jr.

J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):159-66.

PMID:
17146374
3.

Increased health care utilization and increased antiretroviral use in HIV-infected individuals with mental health disorders.

Mijch A, Burgess P, Judd F, Grech P, Komiti A, Hoy J, Lloyd JH, Gibbie T, Street A.

HIV Med. 2006 May;7(4):205-12.

4.

Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.

Bouhnik AD, Préau M, Vincent E, Carrieri MP, Gallais H, Lepeu G, Gastaut JA, Moatti JP, Spire B; MANIF 2000 Study Group.

Antivir Ther. 2005;10(1):53-61.

PMID:
15751763
5.

Severe mental illness at ART initiation is associated with worse retention in care among HIV-infected Ugandan adults.

Nachega JB, Mutamba B, Basangwa D, Nguyen H, Dowdy DW, Mills EJ, Katabira E, Nakimuli-Mpungu E.

Trop Med Int Health. 2013 Jan;18(1):53-7. doi: 10.1111/tmi.12019. Epub 2012 Nov 8.

6.

Mental health disorders and the risk of AIDS-defining illness and death in HIV-infected veterans.

Nurutdinova D, Chrusciel T, Zeringue A, Scherrer JF, Al-Aly Z, McDonald JR, Overton ET.

AIDS. 2012 Jan 14;26(2):229-34. doi: 10.1097/QAD.0b013e32834e1404.

PMID:
22089375
7.
8.

Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients.

Horberg MA, Silverberg MJ, Hurley LB, Towner WJ, Klein DB, Bersoff-Matcha S, Weinberg WG, Antoniskis D, Mogyoros M, Dodge WT, Dobrinich R, Quesenberry CP, Kovach DA.

J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):384-90.

PMID:
18091609
9.

Mortality in HIV-seropositive versus -seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy.

Wang C, Vlahov D, Galai N, Bareta J, Strathdee SA, Nelson KE, Sterling TR.

J Infect Dis. 2004 Sep 15;190(6):1046-54. Epub 2004 Aug 17.

PMID:
15319852
10.
11.

HIV patients with psychiatric disorders are less likely to discontinue HAART.

Himelhoch S, Brown CH, Walkup J, Chander G, Korthius PT, Afful J, Gebo KA.

AIDS. 2009 Aug 24;23(13):1735-42. doi: 10.1097/QAD.0b013e32832b428f.

12.

HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use.

Chander G, Himelhoch S, Fleishman JA, Hellinger J, Gaist P, Moore RD, Gebo KA.

AIDS Care. 2009 May;21(5):655-63. doi: 10.1080/09540120802459762.

13.
14.

[Anhedonia and depressive symptomatology among HIV-infected patients with highly active antiretroviral therapies (ANRS-EN12-VESPA)].

Préau M, Bonnet A, Bouhnik AD, Fernandez L, Obadia Y, Spire B; VESPA.

Encephale. 2008 Sep;34(4):385-93. doi: 10.1016/j.encep.2007.05.004. Epub 2007 Oct 24. French.

PMID:
18922241
15.

Patterns of HIV care for patients with serious mental illness.

Bogart LM, Fremont AM, Young AS, Pantoja P, Chinman M, Morton S, Koegel P, Sullivan G, Kanouse DE.

AIDS Patient Care STDS. 2006 Mar;20(3):175-82.

PMID:
16548714
16.

Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users.

Celentano DD, Galai N, Sethi AK, Shah NG, Strathdee SA, Vlahov D, Gallant JE.

AIDS. 2001 Sep 7;15(13):1707-15.

PMID:
11546947
17.

HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.

Sterling TR, Chaisson RE, Moore RD.

AIDS. 2001 Nov 23;15(17):2251-7.

PMID:
11698698
18.

Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.

Lapadula G, Torti C, Maggiolo F, Casari S, Suter F, Minoli L, Pezzoli C, Di Pietro M, Migliorino G, Ouiros-Roldan E, Ladisa N, Sighinolfi L, Costarelli S, Carosi G; Italian MASTER Cohort.

Antivir Ther. 2007;12(6):941-7.

PMID:
17926648
19.

Impact of antiretroviral therapy on the incidence of tuberculosis: the Brazilian experience, 1995-2001.

Miranda A, Morgan M, Jamal L, Laserson K, Barreira D, Silva G, Santos J, Wells C, Paine P, Garrett D.

PLoS One. 2007 Sep 5;2(9):e826.

20.

Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.

Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, O'Shaughnessy MV, Hogg RS.

CMAJ. 2003 Sep 30;169(7):656-61.

Supplemental Content

Support Center